Drug Profile
HSD 016
Alternative Names: HSD-016Latest Information Update: 16 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Sep 2011 No development reported - Phase-I for Diabetes mellitus in Japan (PO)
- 16 Sep 2011 No development reported - Phase-I for Diabetes mellitus in USA (PO)
- 15 Oct 2009 Wyeth has been acquired by Pfizer